OMERS ADMINISTRATION Corp Takes Position in Vor Biopharma Inc. $VOR

Key Points

• OMERS ADMINISTRATION Corp acquired 139,600 shares of Vor Biopharma Inc. valued at approximately $100,000, marking a small ownership stake of about 0.11% in the company.
• Recent trades indicate significant activity among institutional investors, with Northern Trust Corp increasing its holdings by 39% and Money Concepts Capital Corp boosting theirs by over 106% during the first quarter.
• Vor Biopharma's stock has seen volatility, currently trading around $1.93, with an annual range between $0.13 and $3.29, and analysts rating the stock as a "Moderate Buy" with an average target price of $6.07.

OMERS ADMINISTRATION Corp purchased a new stake in shares of Vor Biopharma Inc. (NYSE:VOR - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 139,600 shares of the company's stock, valued at approximately $100,000. OMERS ADMINISTRATION Corp owned about 0.11% of Vor Biopharma as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Northern Trust Corp boosted its holdings in shares of Vor Biopharma by 39.0% during the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company's stock valued at $175,000 after acquiring an additional 44,252 shares during the last quarter. Money Concepts Capital Corp boosted its holdings in shares of Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after acquiring an additional 26,535 shares during the last quarter. Trustees of Columbia University in the City of New York purchased a new stake in shares of Vor Biopharma during the 4th quarter valued at about $102,000. Finally, Two Sigma Investments LP boosted its holdings in shares of Vor Biopharma by 18.9% during the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock valued at $181,000 after acquiring an additional 25,930 shares during the last quarter. Hedge funds and other institutional investors own 97.29% of the company's stock.

Insider Buying and Selling

In other Vor Biopharma news, major shareholder Reprogrammed Interchange Llc sold 806,351 shares of the firm's stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $2.01, for a total transaction of $1,620,765.51. Following the sale, the insider owned 36,884,567 shares in the company, valued at approximately $74,137,979.67. This trade represents a 2.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders have sold 2,089,534 shares of company stock worth $4,262,465. 0.45% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. JMP Securities reaffirmed a "market perform" rating and set a $6.00 price target on shares of Vor Biopharma in a report on Friday, May 9th. Wedbush reiterated an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. Citizens Jmp cut shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 9th. HC Wainwright reiterated a "buy" rating and issued a $3.00 price objective on shares of Vor Biopharma in a research note on Thursday, August 14th. Finally, Baird R W cut shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Vor Biopharma presently has an average rating of "Moderate Buy" and an average target price of $6.07.

Vor Biopharma Trading Down 3.5%

NYSE VOR opened at $1.93 on Friday. Vor Biopharma Inc. has a 12 month low of $0.13 and a 12 month high of $3.29. The stock has a market cap of $244.50 million, a price-to-earnings ratio of -1.17 and a beta of 2.05. The company's 50 day moving average is $2.08 and its two-hundred day moving average is $1.11.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.